Leerink Partnrs Has Bullish Estimate for Medpace Q3 Earnings

Key Points

• Leerink Partners has increased their Q3 2025 earnings estimate for Medpace to $3.65 per share, just above their previous estimate of $3.64.
• Medpace's recent earnings report showed a 14.2% year-over-year revenue increase with an EPS of $3.10, surpassing expectations of $3.00.
• Analysts currently hold a consensus rating of "Hold" on Medpace stock, with a price target averaging $422.27.

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Leerink Partnrs raised their Q3 2025 earnings estimates for shares of Medpace in a report issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $3.65 per share for the quarter, up from their prior forecast of $3.64. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q4 2025 earnings at $3.73 EPS and FY2025 earnings at $14.14 EPS.

Several other research analysts have also weighed in on MEDP. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Truist Financial lifted their price target on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Finally, Mizuho lifted their price target on shares of Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $422.27.

Medpace Price Performance

Medpace stock opened at $531.00 on Thursday. The company's 50 day simple moving average is $479.93 and its 200 day simple moving average is $372.01. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $547.15. The firm has a market capitalization of $14.92 billion, a price-to-earnings ratio of 39.48, a PEG ratio of 3.35 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. During the same quarter in the previous year, the company earned $2.75 EPS. Medpace's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the period. Brooklyn Investment Group raised its stake in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after acquiring an additional 71 shares in the last quarter. Whittier Trust Co. raised its stake in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after acquiring an additional 35 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of Medpace in the second quarter valued at approximately $36,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Medpace in the first quarter valued at approximately $60,000. Institutional investors own 77.98% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.